1. Treatment with the cholesteryl ester transfer protein inhibitor obicetrapib was associated with reduced major adverse cardiovascular events in high-risk patients on maximally tolerated lipid-lowering therapy.
2. The pooled analysis included data from 2,884 adults with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
3. Obicetrapib produced significant reductions in low-density lipoprotein cholesterol (−37.8%), apolipoprotein B (−21.7%), non–high-density lipoprotein cholesterol (−32.4%), and lipoprotein(a) (−32.5%), and raised high-density lipoprotein cholesterol (+140%) compared with placebo.
4. Cardiovascular benefit became evident after 6 months of treatment, with hazard ratios of 0.60 and 0.45 for four- and three-component major adverse cardiovascular events, respectively.
5. Findings support reconsideration of cholesteryl ester transfer protein inhibition as a therapeutic approach for residual atherogenic risk in patients with established cardiovascular disease.

Source: JACC